Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system?

Jack Burton, Neil Elliot Kay

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Recent evidence of cell membrane expression of interleukin-2 receptors (IL-2R) by malignant B cells in hairy cell leukemia (HCL) and B-chronic lymphocytic leukemia (B-CLL) has lead to speculation that growth factors, such as IL-2, may play a role in the pathophysiology of these diseases. However, to date, it is not clear that IL-2 is a consistent growth factor in vitro or in vivo for malignant B cells. What then is the potential significance of membrane IL-2R on the malignant B-cell membrane? Laboratory analysis indicates that the malignant cells are the source of elevated serum levels of soluble Tac protein (sIL-2rα) in both diseases. Indeed, these cells spontaneously secrete sIL-2Rα into culture medium. We speculate that the presence of an expanding mass of malignant B cells possessing high and low affinity membrane IL-2R may contribute significantly to the associated immunodeficiency seen in B-CLL. In particular, it is the cell associated high affinity IL-2R that have the greatest potential for reducing the levels of free IL-2 available to normal immune cells.

Original languageEnglish (US)
Pages (from-to)92-96
Number of pages5
JournalLeukemia
Volume8
Issue number1
StatePublished - Jan 1994
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
B-Cell Chronic Lymphocytic Leukemia
Immune System
B-Lymphocytes
Down-Regulation
Interleukin-2
Intercellular Signaling Peptides and Proteins
Cell Membrane
Hairy Cell Leukemia
Membrane Potentials
Culture Media
Membranes
Serum
Proteins

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? / Burton, Jack; Kay, Neil Elliot.

In: Leukemia, Vol. 8, No. 1, 01.1994, p. 92-96.

Research output: Contribution to journalArticle

@article{90d315fcc26a4d2499f971a8481766fa,
title = "Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system?",
abstract = "Recent evidence of cell membrane expression of interleukin-2 receptors (IL-2R) by malignant B cells in hairy cell leukemia (HCL) and B-chronic lymphocytic leukemia (B-CLL) has lead to speculation that growth factors, such as IL-2, may play a role in the pathophysiology of these diseases. However, to date, it is not clear that IL-2 is a consistent growth factor in vitro or in vivo for malignant B cells. What then is the potential significance of membrane IL-2R on the malignant B-cell membrane? Laboratory analysis indicates that the malignant cells are the source of elevated serum levels of soluble Tac protein (sIL-2rα) in both diseases. Indeed, these cells spontaneously secrete sIL-2Rα into culture medium. We speculate that the presence of an expanding mass of malignant B cells possessing high and low affinity membrane IL-2R may contribute significantly to the associated immunodeficiency seen in B-CLL. In particular, it is the cell associated high affinity IL-2R that have the greatest potential for reducing the levels of free IL-2 available to normal immune cells.",
author = "Jack Burton and Kay, {Neil Elliot}",
year = "1994",
month = "1",
language = "English (US)",
volume = "8",
pages = "92--96",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system?

AU - Burton, Jack

AU - Kay, Neil Elliot

PY - 1994/1

Y1 - 1994/1

N2 - Recent evidence of cell membrane expression of interleukin-2 receptors (IL-2R) by malignant B cells in hairy cell leukemia (HCL) and B-chronic lymphocytic leukemia (B-CLL) has lead to speculation that growth factors, such as IL-2, may play a role in the pathophysiology of these diseases. However, to date, it is not clear that IL-2 is a consistent growth factor in vitro or in vivo for malignant B cells. What then is the potential significance of membrane IL-2R on the malignant B-cell membrane? Laboratory analysis indicates that the malignant cells are the source of elevated serum levels of soluble Tac protein (sIL-2rα) in both diseases. Indeed, these cells spontaneously secrete sIL-2Rα into culture medium. We speculate that the presence of an expanding mass of malignant B cells possessing high and low affinity membrane IL-2R may contribute significantly to the associated immunodeficiency seen in B-CLL. In particular, it is the cell associated high affinity IL-2R that have the greatest potential for reducing the levels of free IL-2 available to normal immune cells.

AB - Recent evidence of cell membrane expression of interleukin-2 receptors (IL-2R) by malignant B cells in hairy cell leukemia (HCL) and B-chronic lymphocytic leukemia (B-CLL) has lead to speculation that growth factors, such as IL-2, may play a role in the pathophysiology of these diseases. However, to date, it is not clear that IL-2 is a consistent growth factor in vitro or in vivo for malignant B cells. What then is the potential significance of membrane IL-2R on the malignant B-cell membrane? Laboratory analysis indicates that the malignant cells are the source of elevated serum levels of soluble Tac protein (sIL-2rα) in both diseases. Indeed, these cells spontaneously secrete sIL-2Rα into culture medium. We speculate that the presence of an expanding mass of malignant B cells possessing high and low affinity membrane IL-2R may contribute significantly to the associated immunodeficiency seen in B-CLL. In particular, it is the cell associated high affinity IL-2R that have the greatest potential for reducing the levels of free IL-2 available to normal immune cells.

UR - http://www.scopus.com/inward/record.url?scp=0028157196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028157196&partnerID=8YFLogxK

M3 - Article

C2 - 8289505

AN - SCOPUS:0028157196

VL - 8

SP - 92

EP - 96

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -